Clinical Trials for Mesothelioma Patients—A Study of Carboplatin, Bevacizumab and Pemetrexed for MPM Patients
Read about a current clinical trial about the use of Carboplatin, Bevacizumab and Pemetrexed for MPM patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
The purpose of this research study is to evaluate how effective the combination of Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients with Malignant Pleural Mesothelioma (MPM). A combination of cisplatin and pemetrexed is considered standard for this disease and typically off protocol patients would receive cisplatin or carboplatin and pemetrexed as standard of care.
Determine the Overall Survival (OS), (median survival(MS) and 1-yr survival (1-yr S)), in newly diagnosed patients with MPM who are treated with a regimen consisting of cisplatin, bevacizumab, and pemetrexed. Patients will be followed until death and survival curves will be generated. Response rates will be assessed. Secondary:
Estimate the progression free survival (PFS)
Determine the response rates
Safety of the regimen will also be assessed.
The planned length of the study (first subject screened to last subject enrolled) is 24 months. The planned length of the entire study (enrollment period + the treatment period + a follow-up period of at least 12 months) is 36 months.
Phase, Condition and Intervention:
Phase I; Mesothelioma; Drug: Carboplatin, Bevacizumab and PemetrexedStudy Type and Design:
Interventional; Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.